Researchers Invent New Class of Cancer Immunotherapy Drugs

News   Mar 02, 2018 | Original story from Johns Hopkins

 
Researchers Invent New Class of Cancer Immunotherapy Drugs

Design and bifunctional target binding ability of anti-PDL1-TGFβRII. DOI: 10.1038/s41467-017-02696-6

 
 
 

RELATED ARTICLES

Detecting Heart Damage Long Before Parkinson's Symptoms Appear

News

Mapping inflammation in the heart before diagnosis of Parkinson's disease: a new tool for tracking treatment efficacy

READ MORE

Novel ALS Therapy in Human Clinical Trials

News

A phase one/two clinical trial has launched to investigate whether a drug could benefit people with ALS whose disease is caused by mutations in a gene called SOD1

READ MORE

Olfactory Receptors Not Just For Smell Perception

News

Novel cellular functions of olfactory receptors highlighted

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy